You are currently accessing this Site as a guest. Please login or register by clicking Here
Click here to see who are advancing transfusion alternatives and blood management.
Click here and see who are advancing transfusion alternatives and blood management.

Go Back   NoBlood > Resources > Medical Articles and Abstracts


Welcome to NoBlood.

You are currently accessing this Site as a guest which gives you limited access to most discussions and other features. By registering you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, register today!

If you have any problems with the registration process or your account login, please contact contact us. If you forgot your password, click here to request a new one.

Tags: , , , , ,

Reply
 
LinkBack Thread Tools Rate Thread Display Modes
  #1 (permalink)  
Old 06-15-2007, 09:22 PM
Registered User
 
Join Date: Jan 2005
Location: Southeastern Arizona, USA
Posts: 70
Thanks: 1
Thanked 45 Times in 28 Posts
dhcatlady is on a distinguished road
Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa

Gynecol Oncol. 2007 May;105(2):414-7. Epub 2007 Jan 23.

Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer.

Westin SN, Skinner EN, Jonsson Funk M, Gehrig PM, Van Le L.

Department of Gynecologic Oncology, University of North Carolina at Chapel Hill, 4013 Old Clinic, CB 7570, Chapel Hill, NC 27599, USA.

OBJECTIVES: Recombinant epoetin alfa and darbepoetin alfa (r-HuEPO) have been shown to be safe and effective treatments for anemia, but recent reports have suggested an increased risk of thromboembolic events when these agents are used to treat chemotherapy-induced anemia among patients with breast or ovarian cancer. We examined the possible risk of such events among patients with ovarian or primary peritoneal carcinomas and chemotherapy-induced anemia. METHODS: We retrospectively analyzed data over 10 years from women at one hospital with ovarian or primary peritoneal carcinoma and chemotherapy-induced anemia. The incidence and odds ratio for development of deep venous thrombosis, unadjusted and adjusted for baseline differences and risk factors, was assessed between patients who had received r-HuEPO versus no treatment for anemia. RESULTS: Of the 364 women, 90 had received r-HuEPO and 253 had not. The incidence of deep venous thrombosis was 6.7% in the group that had received r-HuEPO and 5.1% in the group that had not (unadjusted odds ratio, 1.31; 95% confidence interval [CI], 0.48-3.55). After adjustment for differences in age, body-mass index, prior thromboembolic disease or cancer, and tobacco use, the odds ratio for developing deep venous thrombosis with the use of r-HuEPO was 1.35 (95% CI, 0.49-3.75). CONCLUSIONS: The use of r-HuEPO was not associated with an increased risk of deep venous thrombosis in this population. A randomized trial is needed to further explore this issue and to detail the safety and efficacy of these agents in patients with various other cancers.

PMID: 17250880 [PubMed - indexed for MEDLINE]

Incidence of symptomatic deep venous thrombosis wi...[Gynecol Oncol. 2007] - PubMed Result
__________________
Debbie D. Holder
Editorial Team
Digg this Post!Add Post to del.icio.usBookmark Post in TechnoratiFurl this Post!
Reply With Quote
Reply

  NoBlood > Resources > Medical Articles and Abstracts



Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools
Display Modes Rate This Thread
Rate This Thread:

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Trackbacks are On
Pingbacks are On
Refbacks are On

Similar Threads
Thread Thread Starter Forum Replies Last Post
Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in pat Sharon Grant Medical Articles and Abstracts 0 10-07-2006 08:53 PM
Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management. Sharon Grant Medical Articles and Abstracts 0 09-26-2006 09:33 PM
Effectiveness of Darbepoetin-Alfa in Combination with Intravenous Iron Sucrose PeterHofland Medical Articles and Abstracts 0 04-02-2006 08:34 PM
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for Nika Medical Articles and Abstracts 0 04-04-2005 10:23 PM
Preoperative administration of epoetin alfa to reduce transfusion requirements in TJ Jan B. Wade Medical Articles and Abstracts 0 06-11-2003 06:57 AM


All times are GMT -7. The time now is 07:51 PM.






! ! ! NEW ! ! !
NoBlood Mobile
NoBlood Mobile
beta

Bloodless Medicine and Surgery Hospitals
Bloodless Medicine and Surgery Hospitals

Featured
Hospital Sponsors

Click here to help us make a difference today. Yes, for the price of a cup of coffee, you can help NoBlood continue its mission to advance knowledge and awareness of transfusion alternatives, blood conservation, blood management, bloodless medicine and bloodless surgery.
Please help us continue to make a difference today.

Highlights
Looking for help?
Can you help?

Key Wiki Articles
Register - FAQ - Members List - Calendar - Files - Videos - Mark Forums Read - NoBlood.org RSS Feeds

Powered by vBulletin® Version 3.6.10
Copyright ©2000 - 2008, Jelsoft Enterprises Ltd.
SEO by vBSEO 3.1.0
Copyright © 1996 - 2008, Bloodless Healthcare International, Inc.